Citations

Showing 10 of 108094 citations.

Skeletal Effects of Inducible ERα Deletion in Osteocytes in Adult Mice
Doolittle, Madison L. , Saul, Dominik , Kaur, Japneet , Rowsey, Jennifer L. , Eckhardt, Brittany, Vos, Stephanie J. B. , Grain, Sarah, Kroupova, Kveta, Ruan, Ming, Weivoda, Megan , Oursler, Merry Jo, Vos, Stephanie, Farr, Joshua N , Monroe, David G , Khosla, Sundeep , Saul, Dominik , Vos, Stephanie, Farr, Joshua N. , Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | July 5, 2022 | Volume: 37 | Issue: 9 | Pages: 1750-1760

10.1002/jbmr.4644 | PMID 35789113 Get It

ABSTRACT Estrogen is known to regulate bone metabolism in both women and men, but substantial gaps remain in our knowledge of estrogen and estrogen receptor alpha (ERα) regulation of adult bone metabolism. Studies using global ERα-knockout mice were confounded by high circulating sex-steroid levels, and osteocyte/osteoblast-specific ERα deletion may be confounded by ERα effects on growth versus the adult skeleton. Thus, we developed mice expressing the tamoxifen-inducible CreERT2 in osteocytes using the 8-kilobase (kb) Dmp1 promoter (Dmp1CreERT2). These mice were crossed with ERαfl//fl mice to create ERαΔOcy mice, permitting inducible osteocyte-specific ERα deletion in adulthood. After intermittent tamoxifen treatment of adult 4-month-old mice for 1 month, female, but not male, ERαΔOcy mice exhibited reduced spine bone volume fraction (BV/TV (−20.1%, p = 0.004) accompanied by decreased trabecular bone formation rate (−18.9%, p = 0.0496) and serum P1NP levels (−38.9%, p = 0.014). Periosteal (+65.6%, p = 0.004) and endocortical (+64.1%, p = 0.003) expansion were higher in ERαΔOcy mice compared to control (Dmp1CreERT2) mice at the tibial diaphysis, reflecting the known effects of estrogen to inhibit periosteal apposition and promote endocortical formation. Increases in Sost (2.1-fold, p = 0.001) messenger RNA (mRNA) levels were observed in trabecular bone at the spine in ERαΔOcy mice, consistent with previous reports that estrogen deficiency is associated with increased circulating sclerostin as well as bone SOST mRNA levels in humans. Further, the biological consequences of increased Sost expression were reflected in significant overall downregulation in panels of osteoblast and Wnt target genes in osteocyte-enriched bones from ERαΔOcy mice. These findings thus establish that osteocytic ERα is critical for estrogen action in female, but not male, adult bone metabolism. Moreover, the reduction in bone formation accompanied by increased Sost, decreased osteoblast, and decreased Wnt target gene expression in ERαΔOcy mice provides a direct link in vivo between ERα and Wnt signaling. © 2022 American Society for Bone and Mineral Research (ASBMR).
Responsiveness and interpretation of the PROMIS Cancer Function Brief 3D Profile
Smith, Sean R. , Vargo, Mary , Zucker, David S., Shahpar, Samman , Henderson, Maryanne, Jay, Gina , Cheville, Andrea , Cheville, Andrea L , Gerber, Lynn H.

Mayo Clinic

Cancer | July 5, 2022 | Volume: 128 | Issue: 17 | Pages: 3217-3223

10.1002/cncr.34376 | PMID 35788990 Get It

BackgroundMeasuring function with valid and responsive tools in patients with cancer is essential for driving clinical decision‐making and for the end points of clinical trials. Current patient‐reported outcome measurements of function fall short for many reasons. This study evaluates the responsiveness of the Patient‐Reported Outcomes Measurement Information System (PROMIS) Cancer Function Brief 3D Profile, a novel measure of function across multiple domains.MethodsTwo hundred nine participants across five geographically distinct tertiary care centers completed the assessment and pain rating at two outpatient cancer rehabilitation clinic visits. Patients and providers completed a global rating of change measure at the second visit to indicate whether the patient was improving or worsening in function. Multiple response indices and linear models measured whether the measure was responsive to self‐reported and clinician‐rated changes over time. Correlations between changes in function and changes in anchors (pain rating and performance status) were also calculated.ResultsFunction as measured by the PROMIS Cancer Function Brief 3D Profile changed appropriately as both patients and clinicians rated change. Small to moderate effect sizes supported the tool's responsiveness. Function was moderately correlated with pain and more strongly correlated with performance status, and changes in function corresponded with changes in anchor variables. No floor/ceiling effect was found.ConclusionsThe PROMIS Cancer Function Brief 3D Profile is sensitive to changes over time in patients with cancer. The measure may be useful in clinical practice and as an end point in clinical trials.Lay summary We gave patients a questionnaire by which they told their physicians how well they were functioning, including how fatigued they were. This study tested that questionnaire to see whether the scores would change if patients got better or worse.
Acute pain pathways: protocol for a prospective cohort study
Jeffery, Molly M. , Ahadpour, Mitra , Allen, Summer V. , Araojo, Richardae , Bellolio, Fernanda , Chang, Nancy, Ciaccio, Laura , Emanuel, Lindsay, Fillmore, Jonathan J., Gilbert, Gregg H. , Koussis, Patricia, Lee, Christine , Lipkind, Heather S. , Mallama, Celeste A. , Meyer, Tamra E. , Moncur, Megan, Nuckols, Teryl K. , Pacanowski, Michael , Page, David B. , Papadopoulos, Elektra J., Ritchie, Jessica , Shah, Nilay D. , Soukup, Mat, Clair, Christopher St. , Tamang, Stephen, Torbati, Sam , Wallace, Douglas W. , Zhao, Yueqin, Heckmann, Rebekah, Jeffery, Molly Moore , Allen, Summer , Fillmore, Jonathan, Bellolio, M Fernanda , Fillmore, Jonathan, Lee, Christine H. , Ross, Joseph S.

Mayo Clinic

BMJ Open | July 5, 2022 | Volume: 12 | Issue: 7 | Pages: e058782

10.1136/bmjopen-2021-058782 | PMID 35790333 Get It

Introduction Opioid analgesics are often used to treat moderate-to-severe acute non-cancer pain; however, there is little high-quality evidence to guide clinician prescribing. An essential element to developing evidence-based guidelines is a better understanding of pain management and pain control among individuals experiencing acute pain for various common diagnoses. Methods and analysis This multicentre prospective observational study will recruit 1550 opioid-naïve participants with acute pain seen in diverse clinical settings including primary/urgent care, emergency departments and dental clinics. Participants will be followed for 6 months with the aid of a patient-centred health data aggregating platform that consolidates data from study questionnaires, electronic health record data on healthcare services received, prescription fill data from pharmacies, and activity and sleep data from a Fitbit activity tracker. Participants will be enrolled to represent diverse races and ethnicities and pain conditions, as well as geographical diversity. Data analysis will focus on assessing patients’ patterns of pain and opioid analgesic use, along with other pain treatments; associations between patient and condition characteristics and patient-centred outcomes including resolution of pain, satisfaction with care and long-term use of opioid analgesics; and descriptive analyses of patient management of leftover opioids. Ethics and dissemination This study has received approval from IRBs at each site. Results will be made available to participants, funders, the research community and the public. Trial registration number NCT04509115 .
Clinical course and imaging characteristics of benign adrenal cysts: a single-center study of 92 patients
Dogra, Prerna , Rivera, Michael , McKenzie, Travis J. , Foster, Trenton R. , Dy, Benzon M. , Lyden, Melanie L. , Bancos, Irina , Young, William F. , Bancos, Irina

Mayo Clinic

European Journal of Endocrinology | July 5, 2022 | Volume: 187 | Issue: 3 | Pages: 429-437

10.1530/eje-22-0285 | PMID 35894855 Get It

Objective Benign adrenal cysts are rare lesions of the adrenal glands. Limited data are available to guide management. We aimed to describe the presentation and outcomes of patients with benign adrenal cysts. Design Retrospective longitudinal cohort study. Methods Consecutive patients with histologically or radiologically confirmed adrenal cysts between 1995 and 2021 were identified. Pheochromocytomas and malignancy were excluded. Results Benign adrenal cysts were diagnosed in 92 patients (53, 57% women) at a median age of 45 years. Mode of discovery was incidental on imaging in 81 (88%), symptoms of mass effect in 9 (9.8%), and others in 2 (2.2%). Majority (89, 97%) of patients had unilateral cysts (45 right, 44 left) with a median size of 48 mm (range 4–200) at diagnosis. On imaging, most cysts were round/oval (85.4%), homogenous (83.2%) lesions with calcifications (64.0%) and no vascular enhancement (97.7%). During a median follow-up of 65 months (range 7–288), adrenal cysts demonstrated minimal enlargement (median size change 6 mm, median growth rate 2 mm/year). On hormonal evaluation, 10% (5/50 tested) had an abnormal overnight dexamethasone suppression test, and 9.5% (4/42 tested) had an abnormal case detection testing for primary aldosteronism. Patients treated with adrenalectomy (46, 50%) were younger (36.9 years vs 50.8 years, P = 0.0009) and had more rapidly enlarging cysts (median growth rate 5.5 mm/year vs 0.4 mm/year, P = 0.0002). Conclusion Benign adrenal cysts are usually incidentally discovered, non-functional, homogenous lesions without vascular enhancement that demonstrate minimal growth. Adrenalectomy should be reserved for patients with heterogeneous lesions, abnormal hormonal evaluation, or those with mass effect symptoms.
A rapid response for burnout among inpatient physiatrists: A survey of leaders of inpatient rehabilitation facilities
Farr, Ellen , Lee, Su-Jin , Maltser, Susan , Shapiro, Lauren T. , Verduzco-Gutierrez, Monica , Shapiro, Lauren T , Verduzco‐Gutierrez, Monica

Mayo Clinic

PM&R | July 5, 2022 | Volume: 14 | Issue: 9 | Pages: 1080-1085

10.1002/pmrj.12870 | PMID 35789206 Get It

Abstract Background Symptoms of burnout are highly prevalent among physiatrists, and prior studies have helped identify key contributors to this epidemic of burnout. Little is known about the physician stressors unique to those providing care in inpatient rehabilitation facilities (IRFs) and what strategies such facilities have used to help mitigate burnout among inpatient physiatrists. Objective To identify what IRF leaders perceive as stress points contributing to burnout among inpatient rehabilitation physicians and what, if any, interventions their programs have implemented to help mitigate physician burnout. Design 10 item cross‐sectional survey study of IRF physician and nonphysician leaders in the United States. Participants 104 physicians serving in the roles of IRF medical director, director of rehabilitation, and/or executive leadership and 19 nonphysician IRF leaders. Results Regulatory demands, late admissions, understaffing, and on‐call responsibilities were the major stress points most identified as contributing to physician burnout among both the physician and nonphysician respondents. The use of advanced practice providers and hospitalists were the most common system changes reportedly used to help mitigate physician burnout. Although 57.8% of physician leaders felt late admissions were a major stress point for physicians, only 18.2% of those responding reported having implemented admission cutoff times. Conclusions There are stressors unique to the practice of inpatient rehabilitation that are likely contributing to physiatrist burnout, including late admissions and on‐call responsibilities. Many IRFs have begun to implement system changes to help mitigate burnout among inpatient physiatrists. The use of nonphysiatrist providers is a commonly reported strategy. Future studies are needed to determine the effectiveness of such a strategy on reducing symptoms of burnout among IRF physicians as well as its effect on IRF patient outcomes.
Racial and Ethnic Disparities in the Trends and Outcomes of Cardiogenic Shock Complicating Peripartum Cardiomyopathy
Olanipekun, Titilope , Effoe, Valery , Egbuche, Obiora , Mather, Paul , Echols, Melvin , Abe, Temidayo , Adedinsewo, Demilade

Mayo Clinic

JAMA Network Open | July 5, 2022 | Volume: 5 | Issue: 7 | Pages: e2220937

10.1001/jamanetworkopen.2022.20937 | PMID 35788668 Get It

Genomic evidence for dysregulated glutamine metabolism in the asthmatic airway epithelium
Bravo‐Solarte, Daniela C. , Stelzig, Kimberly E. , Cuervo‐Pardo, Lyda , Berdnikovs, Sergejs , Chiarella, Sergio E , Stelzig, Kimberly E. , Chiarella, Sergio E.

Mayo Clinic

Clinical and Translational Allergy | July 5, 2022 | Volume: 12 | Issue: 7 | Pages: No page available

10.1002/clt2.12178 | PMID 35813976 Get It

A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient‐reported quality of life
Wong, William W. , Daniels, T.B., Vargas, Carlos , Rwigema, Jean Claude, Corbin, Kimberly S. , Keole, Sameer R., Merrell, Kenneth W. , Stish, Bradley J. , Pisansky, Thomas M. , Mitchell, Cecilia, Choo, Richard , Hillman, David W. , Davis, Brian J. , Mitchell, Cecilia M, Rwigema, Jean‐Claude M.

Mayo Clinic

The Prostate | July 5, 2022 | Volume: 82 | Issue: 14 | Pages: 1338-1345

10.1002/pros.24408 | PMID 35789497 Get It

AbstractBackgroundThe objective of this study was to report acute changes in patient‐reported quality of life (PRQOL) using the 26‐item Expanded Prostate Index Composite (EPIC‐26) questionnaire in a prospective study using hypofractionated intensity‐modulated proton beam therapy (H‐IMPT) targeting the prostate and the pelvic lymph nodes for high‐risk or unfavorable intermediate‐risk prostate cancer.MethodsFifty‐five patients were enrolled. H‐IMPT consisted of 45 GyE to the pelvic lymph nodes and 67.5 GyE to the prostate and seminal vesicles in 25 fractions. PRQOL was assessed with the urinary incontinence (UI), urinary irritative/obstructive symptoms (UO), and bowel function (BF) domains of EPIC‐26 questionnaire. Mean changes in domain scores were analyzed from pretreatment to the end of treatment and 3 months posttreatment. A clinically meaningful change (or minimum important change) was defined as a score change > 50% of the baseline standard deviation.ResultsThe mean scores of UO, UI, and BF at baseline were 84.6, 91.1, and 95.3, respectively. At the end of treatment, there were statistically significant and clinically meaningful declines in UO and BF scores (−13.5 and −2.3, respectively), while the decline in UI score was statistically significant but not clinically meaningful (−13.7). A clinically meaningful decline in UO, UI, and BF scores occurred in 53.5%, 22.7%, and 73.2% of the patients, respectively. At 3 months posttreatment, all three mean scores showed an improvement, with fewer patients having a clinically meaningful decline in UO, UI, and BF scores (18.4%, 20.5%, and 45.0%, respectively). There was no significant reduction in the mean UO and UI scores compared to baseline, although the mean BF score remained lower than baseline and the difference was clinically meaningful.ConclusionsUO, UI, and BF scores of PRQOL declined at the end of H‐IMPT. UO and UI scores showed improvement at 3 months posttreatment and were similar to the baseline scores. However, BF score remained lower at 3 months posttreatment with a clinically meaningful decline.
Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: Early experience
Laughlin, Brady S. , Narang, Gopi L., Cheney, Scott, Humphreys, Mitchell R. , Vargas, Carlos , Keole, Sameer R., Rwigema, Jean‐Claude M. , Wong, William W. , Cheney, Scott M, Schild, Steven E. , Wong, William W , Laughlin, Brady S

Mayo Clinic

Cancer Reports | July 5, 2022 | Volume: 6 | Issue: 1 | Pages: No page available

10.1002/cnr2.1672 | PMID 35790091 Get It

AbstractPurpose/ObjectivesHolmium laser enucleation of the prostate (HoLEP) is commonly performed in patients with significant bladder outlet obstruction. However, there are few reports on the toxicity of external beam irradiation (RT) for prostate cancer in patients after prior HoLEP. In this study, we evaluate the side effects and treatment outcomes of RT after HoLEP.Materials/MethodsEighteen patients who had HoLEP and subsequently received RT for prostate cancer were included. Data collected included patient and disease characteristics, urinary function, and radiation dose. Acute and late urinary (GU) and gastrointestinal (GI) side effects were evaluated. Disease control and survival rates were calculated using Kaplan–Meier method.ResultsMedian follow‐up was 18 months (range: 4–46 months). Median prostate volume was 107 ml before HoLEP and 24 ml after HoLEP. Median International Prostate Symptom Score (IPSS) was 17 (range: 5–32) before HoLEP. Median decline in IPSS score after HoLEP was 7 (range: −2–21). On uroflow study, peak flow rate, and post‐void residual were significantly improved after HoLEP. After radiation, peak flow rate and average flow rate showed a decline but remained significantly improved compared to pre‐HoLEP measurements. Maximum acute Common Terminology Criteria for Adverse Events (CTCAE) adverse events were 12 grade 1 and 3 grade 2 for GU, and 3 grade 1 for GI, respectively. Maximum late adverse events were 13 grade 1 and 2 grade 2 for GU, and all grade 0 for GI, respectively. At last follow‐up, there were 8 grade 1 and 1 grade 2 late GU, and 3 grade 1 late GI adverse events, respectively. There was no significant increase in urinary incontinence after RT compared to before RT. The 18‐month biochemical control, local control, distant control rates were 78%, 94%, and 80%, respectively.ConclusionsPatients who received RT as definitive treatment for prostate cancer after prior HoLEP had low risk of serious acute and late side effects. HoLEP can be safely performed and should be considered in patients with significant bladder outlet obstruction and large prostate volume before RT.
Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry
Fagundes, Antônio , Berg, David D. , Park, Jeong‐Gun , Baird-Zars, Vivian M., Newby, L. Kristin , Barsness, Gregory W. , Miller, P. Elliott , Diepen, Sean van , Katz, Jason N. , Phreaner, Nicholas , Menon, Venu , Daniels, Lori B. , Bohula, Erin A. , Investigators, for the CCCTN, van Diepen, Sean , Roswell, Robert O , Menon, Venu , Daniels, Lori B , Morrow, David A , Bohula, Erin A , Newby, L Kristin , Berg, David , Roswell, Robert O. , Morrow, David A. , Investigators, for the CCCTN

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 5, 2022 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.121.008652 | PMID 35862019 Get It

Background: With the improvement in outcomes for acute coronary syndrome (ACS), the practice of routine admission to cardiac intensive care units (CICUs) is evolving. We aimed to describe the epidemiology of patients with ACS admitted to contemporary CICUs. Methods: Using the CCCTN (Critical Care Cardiology Trials Network) Registry for consecutive medical CICU admissions across 26 advanced CICUs in North America between 2017 and 2020, we identified patients with a primary diagnosis of ACS at CICU admission and compared patient characteristics, resource utilization, and outcomes to patients admitted with a non-ACS diagnosis and across sub-populations of patients with ACS, including by indication for CICU admission. Results: Of 10 118 CICU admissions, 29.4% (n=2978) were for a primary diagnosis of ACS, with significant interhospital variability (range, 13.4%–56.6%). Compared with patients admitted with a diagnosis other than ACS, patients with ACS had fewer comorbidities, lower acute severity of illness with less utilization of advanced CICU therapies (41.3% versus 66.1%, P <0.0001), and lower CICU mortality (5.4% versus 9.9%, P <0.0001). Monitoring alone, without another CICU indication at the time of admission, was the most frequent admission indication in patients with ACS (53.8%); less common indications in patients with ACS included respiratory insufficiency, shock, or the need for vasoactive therapy. Of patients with ACS admitted for monitoring alone, 94.8% did not subsequently require advanced intensive care unit therapies and had a low CICU length of stay (1.5 days [0.9–2.4] versus 2.6 [1.4–5.1], P <0.0001) and CICU mortality (0.6% versus 11.0%, P <0.0001), compared with patients with ACS with an admission indication beyond monitoring. Conclusions: In a registry of tertiary care CICUs, ACS represent ≈1/3 of all admissions with significant variability across hospitals. More than half of the ACS admissions to the CICU were for routine monitoring alone, with a low rate of complications and mortality. This observation highlights an opportunity for prospective studies to refine triage strategies for lower risk patients with ACS.